ArriVent BioPharma appoints new member to board of directors

Newton Square-based ArriVent BioPharma Inc., a clinical-stage company developing biopharmaceutical therapeutics for cancer patients, recently appointed Kristine Peterson to the board of directors.

Peterson has more than 30 years of biopharmaceutical leadership experience.

Peterson most recently was Valeritas CEO. She previously held several executive leadership roles at Johnson & Johnson, served as president and senior vice president of commercial operations for Biovail Corporation, and worked for 20 years at Bristol-Myers Squibb in a variety of senior roles.

Peterson earned a bachelor of science and a M.B.A from the University of Illinois at Urbana-Champaign.

“We are thrilled for Kris to join our board of directors at such an important time for ArriVent, as we advance the development of firmonertinib in multiple non-small cell lung cancer indications,” Bing Yao, ArriVent Chairman and CEO, said. “Kris has a proven track record of strong leadership across the biotech and pharmaceutical industries, with experience successfully launching and commercializing multiple products. Her insight and counsel as a member of our Board will be invaluable as we work to maximize the potential of our pipeline and ensure our medicines reach the patients who need them most.”

Peterson also serves on the boards of Immunocore, Inc. and Enanta Pharmaceuticals.